Paul Hastings Advises 908 Devices in Sale of Bioprocessing PAT Device Portfolio to Repligen Corporation

Paul Hastings LLP advised Boston-based 908 Devices Inc., a pioneer in purpose-built handheld and desktop devices for chemical analysis, in the sale of its desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications to Repligen Corporation, a life sciences company focused on bioprocessing technology leadership.

This transaction demonstrates Paul Hastings’ trajectory in the Boston market — particularly in the life sciences and technology spaces. Mergers and Acquisitions partner Ian Engstrand led the Paul Hastings team, which included partners Andrew Goodman, Lucas Rachuba, Jason Ertel, Todd Schneider, Nikolaos Paschos, Bradley Ritter and Edward Han; of counsel Olivier Souleres and Joerg Ruff; and associates Christopher Shorey, Seung Jin Lee, David Coogan, Maggie Chou, Maren Abraham, Avery Ozimek, Kelsey Massey, Elise Wu and Hannah Edmonds.

More details can be found here.

About Paul Hastings

With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.